b'The only dual ingredient injectable corticosteroid approved by the FDA for use in horsesThe link betweenRAPID ONSET and LONG-ACTING RELIEF of pain & inflammation 1BetaVet (betamethasone sodium phosphate & betamethasone acetate injectable suspension) is indicated for the control of pain and inflammation associated with osteoarthritis in horses. Learn more at www.betavetequine.com or call 1-800-458-0163.Please see Brief Summary of Full Prescribing Information on the following page.INDICATION: BetaVet is indicated for the control of pain and inflammationof clinical signs of laminitis, glucocorticoids should be used with caution in horses associated with osteoarthritis in horses.with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use IMPORTANT SAFETY INFORMATION with caution in horses with chronic nephritis, equine pituitary pars intermedia For Intra-Articular (I.A.) Use in Horses. dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, such as NSAIDs or other corticosteroids, should be CONTRAINDICATIONS: BetaVet is contraindicated in horses with hypersensitivityapproached with caution. Due to the potential for systemic exposure, concomitant to betamethasone. Intra-articular injection of corticosteroids for local effect isuse of NSAIDs and corticosteroids may increase the risk of gastrointestinal, renal, contraindicated in the presence of septic arthritis. and other toxicity. Consider appropriate wash out times prior to administering WARNINGS: Do not use in horses intended for human consumption. Clinical andadditional NSAIDs or corticosteroids. experimental data have demonstrated that corticosteroids administered orally orADVERSE REACTIONS: Adverse reactions reported during a field study of 239 parenterally to animals may induce the first stage of parturition when administeredhorses of various breeds which had been administered either BetaVet (n=119) or during the last trimester of pregnancy and may precipitate premature parturitiona saline control (n=120) at five percent (5%) and above were: acute joint effusion followed by dystocia, fetal death, retained placenta, and metritis.Additionally,and/or local injection site swelling (within 2 days of injection), 15% BetaVet and corticosteroids administered to dogs, rabbits and rodents during pregnancy have13% saline control; increased lameness (within the first 5 days), 6.7% BetaVetresulted in cleft palate in offspring and in other congenital anomalies includingand 8.3% saline control; loose stool, 5.9% BetaVet and 8.3% saline control; deformed forelegs, phocomelia and anasarca. Therefore, before use ofincreased heat in joint, 2.5% BetaVet and 5% saline control; and depression, corticosteroids in pregnant animals, the possible benefits to the pregnant animal5.9% BetaVet and 1.6% saline control. should be weighed against potential hazards to its developing embryo or fetus.DOSAGE AND ADMINISTRATION: Shake well immediately before use. Use Human Warnings: Not for use in humans. For use in animals only. Keep this andimmediately after opening, then discard any remaining contents. all medications out of the reach of children. Consult a physician in the case of accidental human exposure.RX ONLYPRECAUTIONS: Corticosteroids, including BetaVet, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. AcuteReferences: 1. Trotter GW. Intra-articular corticosteroids. In: McIlwraith CW, Trotter GW, eds. Jointmoderate to severe exacerbation of pain, further loss of joint motion, fever, orDisease in the Horse. Philadelphia: W.B. Saunders; 1996; 237256.malaise within several days following intra-articular injection may indicate a2017 Luitpold Animal Health, division of Luitpold Pharmaceuticals, Inc. septic process. Because of the anti-inflammatory action of corticosteroids, signs ofLuitpold Animal Health (logo) and the Horse Head design are trademarksLUITPOLDinfection in the treated joint may be masked. Due to the potential for exacerbationand BetaVet is a registered trademark of Luitpold Pharmaceuticals, Inc.ANIMAL HEALTHPP-BV-US-0010 7/2017'